Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838600 | 1.00 | HTR2C (0.41) | HTR2CHSD11B1HTR2AHTR2BDRD2 | |
| SCHEMBL21838645 | 0.87 | SCN9A (0.45) | HTR2C | |
| SCHEMBL21838629 | 0.87 | SCN9A (0.45) | HTR2C | |
| SCHEMBL21838578 | 0.83 | SCN9A (0.43) | HTR2CDRD2 | |
| SCHEMBL31495941 | 0.81 | HTR2C (0.49) | HTR2CHTR2AHTR2BDRD2KDM1A | |
| SCHEMBL21838641 | 0.76 | KMO (0.37) | HSD11B1AKR1C3AKR1C1 | |
| SCHEMBL21838602 | 0.76 | KMO (0.37) | HSD11B1AKR1C3AKR1C1 | |
| SCHEMBL21294655 | 0.75 | HTR2C (0.48) | HTR2CHTR2AHTR2BDRD2GRIN2B | |
| SCHEMBL31154443 | 0.75 | AKR1C3 (0.62) | HTR2CHTR2AHTR2BDRD2GRIN2B | |
| SCHEMBL31154407 | 0.75 | AKR1C3 (0.62) | HTR2CHTR2AHTR2BDRD2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR2C 1243/4885HSD11B1 316/4885HTR2A 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.